Procedure: spine.On (b)(6) 2014, clinical affairs became aware of a serious adverse event associated with one of covidiens product lines as part of the (b)(6) post-approval study.Two boxes were opened and the site was unable to determine which was used.Subject number: (b)(6).Onset date: (b)(6)-2014.Resolved: continuing.Severity: mild.Relationship to device: definite.Outcome: continuing.Summary of events: subject (b)(6) is an (b)(6) caucasian male with a past medical history of low back pain and degenerative disk disease.The subject had previous surgery at c3/4 and had a loose spinous process removed at t2.On (b)(6) 2014, the subject was admitted to (b)(6), where dr.(b)(6) performed a foraminotomy and decompressive procedure at l2-s1 to treat spinal stenosis.During the procedure: an incidental dural tear occurred, which was closed with sutures.The length of the incision is unk.Duragen was placed over th tear, and the area was then sealed with duraseal (amount unk).Once a watertight closure was obtained, the wound was then closed with sutures.A black drain was placed.On (b)(6) 2014 (post-op dat (b)(6)), swelling and tenderness at the surgical site was noted.The event was diagnosed as a csf leak and treated with a blood patch.The event is currently ongoing.The pt categorized this event was definitely related to duraseal.
|